Fabio Mansani e Felipe Zerwes
08:00 – 08:45
Oral and Posters Local, Regional and Adjuvant
CDIS - Estadiamento (15’)
Primary results of NRG Oncology / NSABP B-43: Phase III trial comparing concurrent trastuzumab (T) and radiation therapy (RT) with RT alone for women with HER2-positive ductal carcinoma in situ (DCIS) after lumpectomy.
Ipsilateral invasive cancer risk after diagnosis with ductal carcinoma in situ (DCIS): Comparison of patients with and without index surgery.
Clinical utility of 18F-FDG-PET/CT in staging localized breast cancer prior to initiating preoperative systemic therapy.
Prognóstico pré-tratamento (15’)
Prognostic impact of high stromal tumor-infiltrating lymphocytes (sTIL) in the absence of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in early stage triple negative breast cancer (TNBC).
Real-world patterns of treatment and recurrence by frailty status among older women with HR-positive, HER2-negative early breast cancer.
Association of intraoperative opioids with improved recurrence-free survival in triple negative breast cancer.
Abstract Brazil (5’)
- Overview of obesity and breast cancer in Brazil: 24 year of follow up.
Darley Ferreira, Rafael Machado
08:45 – 09:40
Cirurgia – Axila
Marina Ávila (15’)
Can sentinel node biopsy after neoadjuvant systemic chemotherapy (NAC) be safely omitted in selected patient with early breast cancer?
Factors associated with axillary conversion after neoadjuvant chemotherapy in initially node positive breast cancer patients: A transSENTINA analysis.
Impact of axillary lymph node dissection (ALND) on survival in patients with ypN1 breast cancer that receive regional nodal irradiation (RNI): A national cancer database (NCDB) analysis.
Neoadjuvância - 1 (15’)
Leonardo Ribeiro Soares
Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).
De-escalated chemotherapy versus endocrine therapy plus pertuzumab+ trastuzumab for HR+/HER2+ early breast cancer (BC): First efficacy results from the neoadjuvant WSG-TPII study.
Efficacy of neoadjuvant chemotherapy (NAC) in male breast cancer (MaBC) compared with female breast cancer (FBC): A National Cancer Database (NCDB) study.
Neoadjuvância - 2 (15’)
Artificial intelligence to accurately identify breast cancer patients with a pathologic complete response for omission of surgery after neoadjuvant systemic therapy: An international multicenter analysis.
Prediction of response to neoadjuvant hormonal therapy (NAHT) using upfront oncotype Dx recurrence score (RS): Results from the SAFIA phase III trial.
Response to neoadjuvant chemotherapy and the 21-gene breast recurrence score in Young women with estrogen receptor-positive early breast cancer.
Daniel Argolo, Waldeir de Almeida Junior
09:40 – 10:25
Abstract Brazil (10’)
- Practice-changing use of 21-gene oncotype DX breast recurrence score assay in a public hospital in Brazil: Results of 155 cases.
- Economic evaluation of the oncotype DX test for hormone receptor positive (HR+) early-stage breast cancer (BC) from the Brazilian societal perspective.
Breast cancer index (BCI) predicts benefit of two-and-a-half versus five years of extended endocrine therapy in HR+ breast cancer patients treated in the ideal trial.
Does chemotherapy affect survival of breast cancer (BC) patients with recurrence score 26-30?
Statistical machine learning model to predict Oncotype DX risk category in women over age 50.
Impact of delays in initiation of adjuvant endocrine therapy and survival among patients with breast cancer.
Abstract Brazil (5’)
Luiz Henrique Gebrim
- Prognostic factors impacting survival in early HER2-positive breast cancer (BC): Results from a 1,142 patients database study.
Adriana Freitas, Vilmar Marques
10:40 – 11:40
Cancer Prevention, Risk Reduction and Genetics (20’)
Alessandra Borba e Fabiana Makdissi
Breast Cancer Highlights Local, Regional and Adjuvant (25’)
Ruffo de Freitas Junior
Cesar Cabello, Francisco Pimentel
11:40 – 12:35
Breast Cancer Metastatic (30’)
Marina Sahade e Max Mano
Plenary Session (10’)
- A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).
João Nunes, José Francisco Rinaldi
Conheça nosso time.